Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03463057
Other study ID # HO151
Secondary ID 2017-002605-35
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date August 30, 2018
Est. completion date January 2027

Study information

Verified date August 2023
Source Stichting Hemato-Oncologie voor Volwassenen Nederland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The prognosis of Diffuse Large B cell Lymphoma (DLBCL) patients with an early relapse is dismal. Atezolizumab has shown promising activity in relapsed DLBCL patients. Toxicity data on atezolizumab are available for > 6000 patients and is manageable. The assumption of this study is that atezolizumab consolidation will result in higher disease free survival by eradicating minimal residual disease In melanoma and lung cancer consolidation immunotherapy after chemoradiotherapy has shown an increase in survival.


Description:

In high risk diffuse large B-cell lymphoma (DLBCL), International Prognostic Index (IPI)-score ≥ 3 21% of patients will relapse within 2-years after completion of R-CHOP induction treatment despite achieving a complete remission. Patient relapsing within a year after R-CHOP treatment have a very poor prognosis, even after second line chemotherapy, with only 15% of patients achieving a long remission. Therefore, additional therapy in first line treatment is required for these patients. The immune checkpoint inhibitor atezolizumab is a monoclonal antibody directed against the program death ligand 1 (PDL1). The PD1 and PDL1 inhibitors have shown excellent results in relapsed Hodgkin lymphoma and promising results in relapsed B-cell non Hodgkin lymphoma. Given the acceptable toxicity profile of atezolizumab, this study examines the efficacy and toxicity of atezolizumab as consolidation treatment after R-CHOP induction in DLBCL patients at high risk of relapse.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 109
Est. completion date January 2027
Est. primary completion date January 18, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age 18-75 (inclusive) years - Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma (DLBCL-NOS) based upon a representative histology specimen according to the World Health Association (WHO) classification, revision 2016 - Ann Arbor stages II-IV - WHO performance status 0 - 1 - International Prognostic Index (IPI) = 3 at diagnosis - Complete metabolic remission (Deauville 1-3) after 6-8 cycles of R-CHOP according to the Lugano criteria Of note: 1. Rituximab may have been administered either intravenously or subcutaneously. A rituximab biosimilar may have been used when it is approved for the indication of DLBCL. 2. Patients should have received at least 6 cycles R-CHOP. Dose reductions for vincristine are allowed during R-CHOP. Dose reductions because of bone marrow toxicity are allowed but cannot exceed >15% of cumulative dose of doxorubicin and cyclophosphamide. 3. Central nervous system prophylaxis (MTX) by intrathecal therapy or IV is allowed. 4. Fludeoxyglucose Positron Emission Tomography (18F-FDG-PET) scan should have been made 4-8 weeks after last induction cycle 5. Histologically confirmed false positive EoT PET-scans are eligible. - Negative pregnancy test at study entry - Patient is willing and able use adequate contraception during and until 5 months after the last protocol treatment. - Patient is capable of giving a written informed consent Exclusion Criteria: Diagnosis • All histopathological diagnoses other than DLBCL-NOS according to the WHO classification, revision 2016, including: - High-grade B-cell lymphoma with a double/triple translocation with MYC, BCL2 and/or BCL6. Please note that patients with an isolated MYC translocation or an isolated BCL2 translocation or an isolated BCL-6 translocation are eligible (single hit translocation). - Testicular large B-cell lymphoma - Primary mediastinal B cell lymphoma - Transformed indolent lymphoma - Post-transplant lymphoproliferative disorder Organ dysfunction - Clinical signs of severe pulmonary dysfunction - Clinical signs of heart failure (New York Heart Association (NYHA) classification II-IV) - Symptomatic coronary artery disease or cardiac arrhythmias not well controlled with medication. - Myocardial infarction during the last 6 months - Significant renal dysfunction (serum creatinine = 150 umol/l or clearance = 30ml/min Creatinine clearance (CrCl) may be calculated by Cockcroft -Gault formula: CrCl = (140 - age [in years]) x weight [kg] (x 0.85 for females)/(0.815 x serum creatinine [µmol/L]) • Inadequate hematological function: hemoglobin < 5.5 mmol/L Absolute Neutrophil Count (ANC) < 1.0x10?9/L or platelets < 75x10?9 /L - Signs or known history of bleeding disorder. - Significant hepatic dysfunction (total bilirubin = 1.5x upper limit of normal (ULN) or transaminases = 2.5 x ULN), unless related to Gilberts syndrome. - Clinical signs of severe cerebral dysfunction - Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs - Major surgery within the last 4 weeks Known or suspected infection • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks of the start of Cycle 1. Suspected active or latent tuberculosis needs to be confirmed by positive interferon gamma (IFN-?) release assay • Patients known to be Human Immuno-deficiency Virus (HIV)-positive - Active chronic hepatitis B or C infection - Administration of a live, attenuated vaccine within 4 weeks before date of registration or anticipation that such a live attenuated vaccine will be required during the study and for a period of 5 months after discontinuation of atezolizumab Auto-immune • Any active or history of documented autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. The following exceptions are allowed: Patients with autoimmune-related hypothyroidism or type 1 diabetes mellitus who are on stable treatment. - History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest computer tomography (CT) scan at screening. - Patients with uncontrolled asthma or allergy, requiring systemic steroid treatment - Regular treatment with corticosteroids within the 4 weeks prior to date of registration, unless administered for indications other than NHL at a dose equivalent to < 30 mg/day prednisone/prednisolone General • Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease) • Current participation in another clinical trial interfering with this trial • History of active cancer during the past 5 years, except basal cell carcinoma of the skin, stage 0 cervical carcinoma or carcinoma in situ (for which no systemic treatment was indicated) • Life expectancy < 6 months • Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule Prior treatment - Prior treatment with Atezolizumab, or anti-programmed cell death protein-1 (anti PD-1) or PDL-1 antibodies. - Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA4 therapeutic antibodies. - Treatment with systemic immunostimulatory agents (including but not limited to IFN, interleukin [IL]-2) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1. - Treatment with systemic immunosuppressive medications, including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) agents within 2 weeks prior to date of registration; inhaled corticosteroids and mineralocorticoids are allowed.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Atezolizumab
Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation

Locations

Country Name City State
Belgium BE-Antwerpen Edegem-UZA Antwerpen
Belgium BE-Antwerpen-ZNASTUIVENBERG Antwerpen
Belgium BE-Brugge-AZBRUGGE Brugge
Belgium BE-Leuven-UZLEUVEN Leuven
Belgium BE-Roeselare-AZDELTA Roeselare
Netherlands NL-Amersfoort-MEANDERMC Amersfoort
Netherlands NL-Amsterdam-OLVG Amsterdam
Netherlands NL-Amsterdam-VUMC Amsterdam
Netherlands NL-Apeldoorn-GELREAPELDOORN Apeldoorn
Netherlands NL-Breda-AMPHIA Breda
Netherlands NL-Delft-RDGG Delft
Netherlands NL-Den Bosch-JBZ Den Bosch
Netherlands NL-Den Haag-HAGA Den Haag
Netherlands NL-Dordrecht-ASZ Dordrecht
Netherlands NL-Ede-ZGV Ede
Netherlands NL-Eindhoven-CATHARINA Eindhoven
Netherlands NL-Eindhoven-MAXIMAMC Eindhoven
Netherlands NL-Enschede-MST Enschede
Netherlands NL-Groningen-UMCG Groningen
Netherlands NL-Hilversum-TERGOOI Hilversum
Netherlands NL-Hoofddorp-SPAARNEGASTHUIS Hoofddorp
Netherlands NL-Leeuwarden-MCL Leeuwarden
Netherlands NL-Leiden-LUMC Leiden
Netherlands NL-Maastricht-MUMC Maastricht
Netherlands NL-Nieuwegein-ANTONIUS Nieuwegein
Netherlands NL-Nijmegen-CWZ Nijmegen
Netherlands NL-Rotterdam-ERASMUSMC Rotterdam
Netherlands NL-Rotterdam-MAASSTADZIEKENHUIS Rotterdam
Netherlands NL-Sittard-Geleen-ZUYDERLAND Sittard
Netherlands NL-Tilburg-ETZ Tilburg
Netherlands NL-Utrecht-UMCUTRECHT Utrecht
Netherlands NL-Zwolle-ISALA Zwolle

Sponsors (1)

Lead Sponsor Collaborator
Stichting Hemato-Oncologie voor Volwassenen Nederland

Countries where clinical trial is conducted

Belgium,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Atezolizumab spinal fluid concentration as assessed by spinal fluid measurements will be performed in patients receiving atezolizumab. To assess the crossing of the blood-brain barrier of atezolizumab by measuring atezolizumab concentrations in het cerebrospinal fluid. 2 years after inclusion last patient
Primary Disease free survival (DFS) measured from the date of registration to relapse or death from any cause whichever comes first. To evaluate the 2-year DFS for patients in complete metabolic remission after R-CHOP induction 2 year after inclusion last patient
Secondary (Severe) Adverse Events and the relation of adverse events in time to the recovery of the T-cell repertoire. To evaluate toxicity and assess the relation of adverse events in time to recovery of the T-cell repertoire. 2 years after inclusion last patient
Secondary Overall survival (OS), calculated from registration until death from any cause. Patients still alive or lost to follow up are censored at the last date known to be alive. To evaluate the 2-year OS. 2 years after inclusion last patient
Secondary The relationship between MRD status at the end-of-induction and end-of-consolidation therapy. To evaluate MRD status at the end of induction therapy, at various time points during consolidation treatment and at the end of consolidation. 2 years after inclusion last patient
Secondary The relation between MRD conversion and 2-years DFS and OS. To evaluate if there is a relation between MRD conversion and 2-years DFS and OS. 2 years after inclusion last patient
Secondary The relation between the T-cell and NK cell repertoire and adverse events. To evaluate the recovery of the T-cell and NK cell repertoire after induction therapy and at various time points during consolidation treatment in relation to toxicity and efficacy. 2 years after inclusion last patient
See also
  Status Clinical Trial Phase
Recruiting NCT05552937 - Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL Phase 2
Completed NCT03287817 - CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Not yet recruiting NCT05039658 - Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) Phase 1
Completed NCT01205737 - A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects Phase 1
Recruiting NCT04594798 - A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL Phase 2
Active, not recruiting NCT04088890 - Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Phase 1
Active, not recruiting NCT04566978 - 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) Early Phase 1
Completed NCT03672682 - SMOLY : Phenotype and Functions of Monocyte Subtypes in High Grade B Lymphoma: Towards New Biomarkers?
Active, not recruiting NCT03997968 - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03954106 - A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity Phase 2
Active, not recruiting NCT02889523 - Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy Phase 1/Phase 2
Recruiting NCT05546268 - Study of Oral MRT-2359 in Selected Cancer Patients Phase 1/Phase 2
Not yet recruiting NCT05498636 - SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression Phase 1/Phase 2
Not yet recruiting NCT04994626 - Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies Phase 2
Recruiting NCT04072458 - A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies Phase 1
Recruiting NCT03758989 - A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma Phase 2
Recruiting NCT04792489 - DALY 2.0 USA/ MB-CART2019.1 for DLBCL Phase 2
Terminated NCT02698189 - A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) Phase 1
Recruiting NCT05414162 - Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

External Links